needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, any commercialization efforts or other operations;5Table of Contents•we are substantially dependent on the success of our current product candidate, PRT-201, and cannot guarantee that this
successfully complete the development and commercialization of PRT-201 or any additional product candidates.We began enrolling patients in our first Phase 3 clinical trial of PRT-201 during the third quarter of 2014 for patients undergoing placement of radiocephalic AVFs. Prior to
business, financial condition and results of operations.We have never generated any revenue from product sales and may never be profitable.As a company, we have never obtained regulatory approval for, or commercialized, any product candidate.
development of any additional product candidates;•seeking and obtaining regulatory and marketing approvals for PRT-201 if and when we complete clinical trials;•establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in
A decline in the value of our company could also cause you to lose all or part of your investment.Risks Related to Clinical Development, Regulatory Review and Approval of Our ProductWe are substantially dependent on the success of our current product candidate, PRT-201, and cannot guarantee that this product candidate will successfully complete
commercializing PRT-201 will have a substantial adverse impact on our business and financial condition.We have not previously submitted a BLA to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that PRT-201 or
we continue to develop PRT-201 for other indications, including AVG, brachiocephalic AVF and PAD, or additional product candidates, we will face similar risks and challenges.Clinical development is a lengthy and expensive process with an uncertain outcome due to many factors.
Any Phase 3 or other clinical trial that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market PRT-201 or any additional product
approvals would prevent or delay commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations.PRT-201 and any additional product candidates are subject to extensive governmental regulations relating to, among other things,
which would have an adverse effect on our business.19Table of ContentsIf we experience any of a number of possible unforeseen events in connection with clinical trials of PRT-201 or any additional product candidates, potential marketing
approval or commercialization of PRT-201 or any additional product candidates could be delayed or prevented.We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent marketing approval
many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of marketing approval of PRT-201 or any additional product candidates.Any product for which we obtain FDA approval will be subject to extensive ongoing regulatory requirements, and Proteon may be subject to penalties if it fails to comply with
Sales of PRT-201 or any additional product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing
the regulation of pharmaceutical and biotechnology products and treatment; and24Table of Contents•the acceptability of data obtained from trials conducted outside the United States to the FDA in support of a BLA.Risks Related to Commercialization of Our ProductIf we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, if they are
we may be delayed in completing, or unable to complete, the clinical trials required to support future approval of PRT-201 or any additional product candidates.We
or operations, including the bankruptcy of the manufacturer or supplier.Any of these events could lead to delays in the development of PRT-201 or any additional product candidates, including delays in our clinical trials, or failure to obtain regulatory
expected deadlines, we may not be able to obtain regulatory approval for, or commercialize, PRT-201 or any additional product candidates and our business could be substantially harmed.We rely on CROs and clinical trial sites to ensure our clinical trials are conducted properly and on time.
factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of PRT-201 or any additional product candidates, cause us to incur
commercial relationships or capital commitments;•our ability to successfully market PRT-201 or any additional product candidates;•changes in laws and regulations affecting our business, including but not limited to clinical trial requirements for